tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Digestive System Fistula D016154 1 associated lipids
Crigler-Najjar Syndrome D003414 1 associated lipids
Leukoplakia, Oral D007972 1 associated lipids
Peroneal Neuropathies D020427 1 associated lipids
Poxviridae Infections D011213 1 associated lipids
Kaposi Varicelliform Eruption D007617 1 associated lipids
Lacerations D022125 1 associated lipids
Megacolon, Toxic D008532 1 associated lipids
Tinea Capitis D014006 1 associated lipids
Polyomavirus Infections D027601 1 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Kuo CJ et al. Rapamycin selectively inhibits interleukin-2 activation of p70 S6 kinase. 1992 Nature pmid:1614535
Thomson AW et al. FK 506, cardiac transplantation, and graft-vessel disease. 1992 Lancet pmid:1370563
Takahara S et al. The in vitro immunosuppressive effect of deoxymethylspergualin in man as compared with FK506 and cyclosporine. 1992 Transplantation pmid:1373537
Johnson MC et al. QT prolongation and Torsades de Pointes after administration of FK506. 1992 Transplantation pmid:1373538
Kim YI et al. Stimulation of liver regeneration by pretreatment with azathioprine as well as cyclosporine and FK506. 1992 Transplantation pmid:1373539
Carobbi A et al. Synergism of splenectomy and immunosuppressive drugs in prolongation of cardiac xenograft survival. 1992 Transplant. Proc. pmid:1373543
Yamada K et al. New morphological changes induced by FK506 in a short period in the rat kidney and the effect of superoxide dismutase and OKY-046 on THEM: the relationship of FK506 nephrotoxicity to lipid peroxidation and change in production of thromboxane A2 in the kidney. 1992 Transpl. Int. pmid:14621878
Tai PK et al. Association of a 59-kilodalton immunophilin with the glucocorticoid receptor complex. 1992 Science pmid:1376003
Jegasothy BV et al. Tacrolimus (FK 506)--a new therapeutic agent for severe recalcitrant psoriasis. 1992 Arch Dermatol pmid:1376102
Wiederrecht G et al. Isolation of a human cDNA encoding a 25 kDa FK-506 and rapamycin binding protein. 1992 Biochem. Biophys. Res. Commun. pmid:1376117
Mor E et al. Late-onset acute rejection in orthotopic liver transplantation--associated risk factors and outcome. 1992 Transplantation pmid:1279849
Hirano Y et al. The effects of FK506 and cyclosporine on the exocrine function of the rat pancreas. 1992 Transplantation pmid:1279850
Takaya S et al. Liver transplantation in positive cytotoxic crossmatch cases using FK506, high-dose steroids, and prostaglandin E1. 1992 Transplantation pmid:1279851
Renoir JM et al. [Effect of immunosuppressants FK506 and rapamycin on the function of progesterone receptor: protein "p59-HBI", intersection between immunology and endocrinology?]. 1992 C. R. Acad. Sci. III, Sci. Vie pmid:1284044
Natazuka T FK506 reverses adriamycin resistance in a multidrug-resistant human leukemia cell line. 1992 Kobe J Med Sci pmid:1284834
Tocci MJ and Sigal NH Recent advances in the mechanism of action of cyclosporine and FK506. 1992 Curr. Opin. Nephrol. Hypertens. pmid:1285380
Bavandi A et al. Diet-induced dermatitis response of hairless rats to systemic treatment with cyclosporin A (Sandimmun), cyclosporin H and FK506. 1992 Exp. Dermatol. pmid:1285411
Iwasaki K et al. Effect of repeated oral doses of a novel immunosuppressive macrolide lactone on hepatic mixed-function oxidase system in the rat. Comparative study with ciclosporin. 1992 Arzneimittelforschung pmid:1379812
Takada K et al. Distribution kinetics of FK-506, a novel immunosuppressant, after intravenous administration to rats in comparison with cyclosporin A. 1992 Biopharm Drug Dispos pmid:1379839
Christians U et al. Specific and sensitive measurement of FK506 and its metabolites in blood and urine of liver-graft recipients. 1992 Clin. Chem. pmid:1382896
Fruman DA et al. Correlation of calcineurin phosphatase activity and programmed cell death in murine T cell hybridomas. 1992 Eur. J. Immunol. pmid:1382988
Mittrücker HW and Fleischer B Functional localization of an exocytosis-triggering G-protein in human cytotoxic T lymphocytes. 1992 Immunology pmid:1383135
Wang SC et al. FK-506 inhibits proliferation and IL-4 messenger RNA production by a T-helper 2 cell line. 1992 J. Surg. Res. pmid:1383612
Jordan ML et al. Initial studies with FK506 in renal transplantation. 1991 Sep-Oct Cleve Clin J Med pmid:1718631
Siekierka JJ et al. Potential roles of other FK 506-binding proteins in mediating the effects of FK 506. 1991 Transplant. Proc. pmid:1721256
Morris RE In vivo immunopharmacology of the macrolides FK 506 and rapamycin: toward the era of rational immunosuppressive drug discovery, development, and use. 1991 Transplant. Proc. pmid:1721257
Kobayashi M et al. FK 506 assay past and present--characteristics of FK 506 ELISA. 1991 Transplant. Proc. pmid:1721258
Warty VS et al. Practical aspects of FK 506 analysis (Pittsburgh experience). 1991 Transplant. Proc. pmid:1721259
Jusko WJ and D'Ambrosio R Monitoring FK 506 concentrations in plasma and whole blood. 1991 Transplant. Proc. pmid:1721260
Venkataramanan R et al. Pharmacokinetics of FK 506 in transplant patients. 1991 Transplant. Proc. pmid:1721261
Christians U et al. High performance liquid chromatography/mass spectrometry of FK 506 and its metabolites in blood, bile, and urine of liver grafted patients. 1991 Transplant. Proc. pmid:1721262
Blanc P et al. Antiproliferative effect of FK 506 and cyclosporine on adult human hepatocytes in culture. 1991 Transplant. Proc. pmid:1721288
Loréal O et al. FK 506 is less cytotoxic than cyclosporine to human and rat hepatocytes in vitro. 1991 Transplant. Proc. pmid:1721289
McCauley J et al. Cyclosporine and FK 506 induced inhibition of renal epithelial cell proliferation. 1991 Transplant. Proc. pmid:1721290
McLachlan G et al. Growth inhibition of the MOLT-4 human T-leukemia cell line. A comparison of cyclosporine and FK 506. 1991 Transplant. Proc. pmid:1721291
Akselband Y et al. Rapamycin inhibits spontaneous and fibroblast growth factor beta-stimulated proliferation of endothelial cells and fibroblasts. 1991 Transplant. Proc. pmid:1721292
Schreiber SL et al. Immunophilin-ligand complexes as probes of intracellular signaling pathways. 1991 Transplant. Proc. pmid:1721293
Chen-Woan M et al. Diminished lymphocyte growth from endomyocardial biopsies from cardiac transplant patients on FK 506 immunosuppression. 1991 Transplant. Proc. pmid:1721320
Fukuzawa M et al. Effect of FK 506 on CD4+ and CD8+ T-cell function in vivo. 1991 Transplant. Proc. pmid:1721321
Takaori K et al. Effects of FK 506 on in vivo immunity in comparison to cyclosporine. 1991 Transplant. Proc. pmid:1721322
Jordan ML et al. Inhibition of T-cell function by FK 506 and cyclosporine is not accompanied by alterations in intracellular calcium. 1991 Transplant. Proc. pmid:1721323
Motta I et al. FK 506 favors the generation of memory T cells in vitro. 1991 Transplant. Proc. pmid:1721324
Nakata S et al. Immunosuppressive effect of FK 506 on cytotoxic T lymphocytes and delayed-type hypersensitivity in rats. 1991 Transplant. Proc. pmid:1721325
Cooper MH et al. Evaluation of the influence of FK 506, rapamycin, and cyclosporine on processing and presentation of particulate antigen by macrophages: assessment of a drug "carry-over" effect. 1991 Transplant. Proc. pmid:1721326
Green M et al. Infectious complications of pediatric liver transplantation under FK 506. 1991 Transplant. Proc. pmid:1721352
Carroll PB et al. Effect of the immunosuppressant FK506 on glucose-induced insulin secretion from adult rat islets of Langerhans. 1991 Transplantation pmid:1702911
Torre-Cisneros J et al. The spectrum of aspergillosis in liver transplant patients: comparison of FK 506 and cyclosporine immunosuppression. 1991 Transplant. Proc. pmid:1721353
Starzl TE et al. Hepatotrophic effects of FK506 in dogs. 1991 Transplantation pmid:1702912
Paul AA et al. CMV retinitis and the use of FK 506. 1991 Transplant. Proc. pmid:1721354
Keicho N et al. Effects of an immunosuppressant, FK506, on interleukin 1 alpha production by human macrophages and a macrophage-like cell line, U937. 1991 Cell. Immunol. pmid:1703047
Reyes J et al. Posttransplant lymphoproliferative disorders occurring under primary FK 506 immunosuppression. 1991 Transplant. Proc. pmid:1721355
White DJ FK506: the promise and the paradox. 1991 Clin. Exp. Immunol. pmid:1703053
Whiteside TL et al. Serial monitoring of immunologic function and phenotype of lymphocytes in the blood of transplanted patients randomized to cyclosporine or FK 506. 1991 Transplant. Proc. pmid:1721356
Frayha HH et al. Lymphoproliferative disorder in a liver transplant patient on FK 506. 1991 Lancet pmid:1703258
Van Thiel DH et al. Interferon therapy of hepatitis following liver transplantation under FK 506 or cyclosporine. 1991 Transplant. Proc. pmid:1721357
Burman K and Crawford DH Effect of FK 506 on Epstein-Barr virus specific cytotoxic T cells. 1991 Lancet pmid:1703259
McCauley J et al. Changes in renal function after liver transplantation under FK 506. 1991 Transplant. Proc. pmid:1721385
Tauxe WN et al. A comparison of the renal effects (ERPF, GFR, and FF) of FK 506 and cyclosporine in patients with liver transplantation. 1991 Transplant. Proc. pmid:1721386
McCauley J et al. Renal function after conversion from cyclosporine to FK 506 in liver transplant patients. 1991 Transplant. Proc. pmid:1721387
Hossein-Nia M et al. Urinary proteins as a marker of drug-induced renal damage following treatment with cyclosporine or FK 506. 1991 Transplant. Proc. pmid:1721388
Winkler M et al. Association of elevated FK 506 plasma levels with nephrotoxicity in liver-grafted patients. 1991 Transplant. Proc. pmid:1721389
Schmidt RJ et al. Hemolytic-uremic syndrome in a renal transplant recipient on FK 506 immunosuppression. 1991 Transplant. Proc. pmid:1721390
Tze WJ et al. Effect of FK 506 on glucose metabolism and insulin secretion in normal rats. 1991 Transplant. Proc. pmid:1721391
Fukuzaki T et al. Induction of tolerance to islet allografts with preoperative donor spleen cell injection and a short course of FK 506 treatment. 1991 Transplant. Proc. pmid:1721415
Tzakis AG et al. FK 506 rescue in chronic graft-versus-host-disease after bone marrow transplantation. 1991 Transplant. Proc. pmid:1721416
Masaoka T et al. Phase II study of FK 506 for allogeneic bone marrow transplantation. 1991 Transplant. Proc. pmid:1721417
Markus PM et al. The effect of cyclosporine, rapamycin and FK 506 the survival following allogeneic bone marrow transplantation. 1991 Transplant. Proc. pmid:1721418
Cooper MH et al. The induction of pseudo-graft-versus-host disease following syngeneic bone marrow transplantation using FK 506. 1991 Transplant. Proc. pmid:1721419
Boggs S et al. FK 506 has no short-term effects on endogenous or exogenous myeloid reconstitution in irradiated mice. 1991 Transplant. Proc. pmid:1721420
Cooper MH et al. Prolonged prevention of acute graft-versus-host disease after allogeneic bone marrow transplantation by donor pretreatment using FK 506. 1991 Transplant. Proc. pmid:1721421
Van Duyne GD et al. Atomic structure of FKBP-FK506, an immunophilin-immunosuppressant complex. 1991 Science pmid:1709302
Lim SM and White DJ The pharmacology of immunosuppression. 1991 Ann. Acad. Med. Singap. pmid:1709344
Rosen MK et al. Proton and nitrogen sequential assignments and secondary structure determination of the human FK506 and rapamycin binding protein. 1991 Biochemistry pmid:1709363
Sakr MF et al. FK 506 ameliorates the hepatic injury associated with ischemia and reperfusion in rats. 1991 Hepatology pmid:1709412
Hohlfeld R [Current therapy of multiple sclerosis: value of cyclosporin A and FK 506]. 1991 Nervenarzt pmid:1709725
Kay JE et al. Inhibition of T and B lymphocyte proliferation by rapamycin. 1991 Immunology pmid:1709916
Ringe D Immunosuppression. Binding by design. 1991 Nature pmid:1710317
Fabrega AJ et al. FK 506 enhances the beneficial effects of donor-specific blood transfusion on allograft survival in rats. 1991 Transplant. Proc. pmid:1721447
Davies CB et al. Effects of donor-specific transfusion, cyclosporine A and FK 506 on rat cardiac allograft survival. 1991 Transplant. Proc. pmid:1721448
Abu-Elmagd K et al. FK 506: a new therapeutic agent for severe recalcitrant psoriasis. 1991 Transplant. Proc. pmid:1721449
Nikolaidis NL et al. Metabolic effects of FK 506 in patients with severe psoriasis: short-term follow-up of seven cases. 1991 Transplant. Proc. pmid:1721450
Abu-Elmagd K et al. Efficacy of FK 506 in the treatment of recalcitrant pyoderma gangrenosum. 1991 Transplant. Proc. pmid:1721451
Thomson AW et al. Influence of FK 506 on T lymphocytes, Langerhans' cells and the expression of cytokine receptors and adhesion molecules in psoriatic skin lesions: a preliminary study. 1991 Transplant. Proc. pmid:1721452
Jin YJ et al. Molecular cloning of a membrane-associated human FK506- and rapamycin-binding protein, FKBP-13. 1991 Proc. Natl. Acad. Sci. U.S.A. pmid:1713687
Murase N et al. Long survival in rats after multivisceral versus isolated small-bowel allotransplantation under FK 506. 1991 Surgery pmid:1714104
Lodish HF and Kong N Cyclosporin A inhibits an initial step in folding of transferrin within the endoplasmic reticulum. 1991 J. Biol. Chem. pmid:1714445
Ellis D et al. Phospholipase-C and Na-K ATPase activation by cyclosporine and FK506 in LLC-PK1, cells. Possible implications in blood pressure regulation. 1991 Transplantation pmid:1714643
Simmons RL and Wang SC New horizons in immunosuppression. 1991 Transplant. Proc. pmid:1714645
Calne RY Immunosuppression for organ grafting. 1991 Transplant. Proc. pmid:1714646
Ochiai T et al. [Immunosuppressive agents--advances of the developmental studies and the mode of action]. 1991 Nippon Rinsho pmid:1715926
Ricordi C et al. In vivo effect of FK506 on human pancreatic islets. 1991 Transplantation pmid:1716797
Katz IA et al. Comparison of the effects of FK506 and cyclosporine on bone mineral metabolism in the rat. A pilot study. 1991 Transplantation pmid:1716801
Jiang H et al. Effect of FK-506 on heart allograft survival in the highly sensitized recipient rats as compared with ciclosporin and 15-deoxyspergualin. 1991 Eur Surg Res pmid:1723683
Pezze JL and Whiteman K Transplantation's newest weapon FK 506. 1991 Am J Nurs pmid:1716857
Fung JJ et al. Conversion of liver allograft recipients from cyclosporine to FK 506-based immunosuppression: benefits and pitfalls. 1991 Transplant. Proc. pmid:1703682
Marquis-Omer D et al. Stabilization of the FK506 binding protein by ligand binding. 1991 Biochem. Biophys. Res. Commun. pmid:1716886
Wu J et al. Comparative immunoregulatory effects of rapamycin, FK 506 and cyclosporine on mitogen-induced cytokine production and lymphoproliferation. 1991 Transplant. Proc. pmid:1703683
Sakai K et al. [The effect of a new immunosuppressive agent, FK-506, on xenogeneic neural transplantation in rodents--comparison with cyclosporin A]. 1991 No To Shinkei pmid:1716937
Yoshimura R et al. A comparative study between cyclosporine and FK 506 effects on renal microsomal P-450. 1991 Transplant. Proc. pmid:1703686
Miyagawa S et al. Mechanism of unresponsiveness in rats induced by a short course of FK 506 or CyA. 1991 Transplant. Proc. pmid:1703687